The demand for unrelated haematopoietic cell (HPC) donors has risen threefold over the last decade, and is likely to continue to rise over the next 10 years. The time taken from diagnosis to transplant is recognised to adversely affect patient outcome, and provision of unrelated donors (UDs) has been identified as a key source of delay. Obstacles to provision of UD include: delays in referral to a transplant centre, awaiting sibling typing, lack of matched donors (particularly for those from ethnic minorities and/or with rare HLA phenotypes), low-or intermediate-resolution donor HLA typing, donor attrition from the registries, donor ineligibility on grounds of health and difficulties encountered transporting HPC across international borders. There are now over 18 million volunteer donors in registries worldwide, and efficiency has improved, at least in part, because of a switch from paper to electronic searches. As a result, the average time from search request to transplant is estimated to be less than half of what it was two decades ago. Furthermore, registries have developed a number of strategies designed to minimise delays and, ultimately, improve patient outcomes. These include: optimisation of donor numbers and ethnic mix through focused and selective recruitment; high-resolution typing at donor recruitment; cord blood banking with aggressive recruitment in ethnic minorities; early identification of those unlikely to find a match so alternative transplant options may be pursued in a timely manner, through use of HLA-based predictive algorithms; reduction of donor attrition; centralised, registrybased, donor identification services; and provision of a back-up donor.
INTRODUCTION
Allogeneic haematopoietic cell (HPC) transplantation is a curative procedure for patients with a wide variety of malignant and nonmalignant disorders. 1 The last 10 years have seen a threefold increase in the number of recipients of HPCs from unrelated donors (UDs), 2 because of a significant reduction in transplantrelated mortality 3 permitting transplantation in those previously thought to be ineligible (such as older patients), an ever-increasing number of indications 4, 5 and the advent of an international centralised UD search system. 6, 7 This number is likely to increase further in the coming decade, such that the National Marrow Donor Program (NMDP) anticipates a doubling in the number of unrelated HPC donations by the end of this decade. 8 A central paradigm in UD transplantation is the provision of a donor genetically matched to a patient at key HLA loci, as a poor match may significantly affect patient outcome. In the United Kingdom, matched allele pairs at HLA-A, -B, -C w , -DRB1 and -DQB1 (the 10/10 match) is considered optimal: overall survival, transplant-related mortality, relapse, engraftment and GVHD have all been adversely associated with increasing degrees of HLAmismatch. 9 --13 The development of DNA-based typing methods capable of determining HLA phenotypes to high resolution has allowed much greater discrimination between donors compared with traditional low-resolution serological techniques, and this has improved outcomes. 9,14 --17 Inevitably, a proportion of patients will never proceed to transplant, either because an appropriately matched donor cannot be found, or because medical complications in the patient intervene. Others will encounter delays in the pre-transplant period (even after a donor has been identified), and these delays are adversely associated with patient outcome. Frassoni et al. 18 found in 427 patients with AML achieving a first CR who waited 93 days or more for transplant had increased transplant-related mortality, compared with those waiting o93 days (relative risk 1.79, P ¼ 0.03). Craddock et al., 19 in a cohort of 168 patients with primary refractory AML, found a time to transplant from diagnosis of o4 months to be significantly correlated to improved overall and leukaemia-free survival at 5 years. Finally, in a study of 548 transplant patients, Heemskerk et al. 20 found that 30% of patients became medically unfit while waiting for an UD transplant. Taking into account factors such as disease risk, age and gender, they concluded that shortening the time taken for donor provision was key to reducing this rate of clinical deterioration.
A number of obstacles may be encountered in the provision of unrelated HPC donors ( Figure 1 ). Many patients are diagnosed in a non-transplant clinical environment, and there may be a delay in referral to a transplant centre. Results of sibling typing may be awaited before initiating an UD search. There may be no matched donor found through national or international registry searches, donors may be typed only at low-resolution, or the individual analysing the search report may not be sufficiently experienced to select the optimum donor. Once selected for confirmatory typing (CT), the donor may be untraceable, unavailable or medically ineligible for donation. Finally, the donor may be unable to meet the timescale demanded by the transplant centre, there may be delays because of carriage of cells across international borders, or there may be damage or contamination to the cell product in transit.
In this first part of this review, the key factors influencing each stage of unrelated HPC donor provision will be discussed, followed by a summary of current strategies designed to minimise any potential delay they may cause, improve operational efficiency and, ultimately, improve patient outcomes.
KEY REASONS FOR DELAYS IN UD PROVISION Pre-search factors
The time between the diagnosis of a condition for which allogeneic HPC transplant is recommended and initiation of an UD search may be prolonged by a number of factors. Many patients will not be diagnosed in a transplant centre, but may undergo induction therapy there nonetheless. Physicians less experienced in transplantation may not appreciate the time it takes to procure an UD, and miss the opportunity for early referral to a transplant centre or initiating a search process.
In addition, an UD search is often not initiated until it is clear that an HLA-identical sibling is unavailable. In some cases, particularly when siblings are estranged or overseas, this can cause undue delay.
Donor search, and the characteristics of the international donor inventory The international donor inventory encompasses a centralised database of donor HLA phenotypes, and other relevant data, from UD registries across the world, facilitating the provision of matched donors regardless of international borders. 7 The composition of the inventory is influenced by a number of factors, including donor motivations, HLA diversity, ethnicity, typing resolution and non-HLA discriminators, such as gender, age and CMV status.
The stem cell donor. At the roots of any donor registry are the donors themselves. Stem cell donation is an altruistic, voluntary and, at least currently, unpaid gesture. Positive motivations vary among UDs and may include solidarity, or a wish to act according to social or religious precepts, expected positive feelings about donating, empathy for the recipient and a desire to help another person. 21 There are a number of negative factors that have been documented to affect a donor's willingness to donate, including cost, perception of risk and likelihood of being asked to donate. Motivations also vary by gender, age and the method of recruitment. 22 --24 HLA. The six, highly polymorphic, HLA molecules (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1), encoded by the MHC on chromosome 6, are ubiquitous cell surface markers that have a key role in the recognition of foreign Ags 25 and the formation of tolerance to self and foetal Ags. 26, 27 Both these concepts are important in SCT, in particular influencing engraftment and the incidence of GVHD. Matching for HLA-A, -B, -C, -DRB1 and -DQB1 molecules (10/10 match) has been found to be key in improving the outcome of HPC transplantation.
Owing to a recombination hotspot in the HLA class II region, 28 UDs are most often mismatched (480%) with the patient at HLA-DPB1 despite being matched for the other HLA loci. 29 For this reason, HLA-DPB1 has not been included in global donor selection strategies. In addition, studies over the last 10 years have shown an increase in GVHD associated with a DPB1 mismatch, which is offset by a decrease in disease relapse, resulting in no additional survival benefit. 30 --33 Recently, however, there is emerging data supportive of the impact of permissive (clinically tolerated) vs non-permissive (clinically detrimental) mismatches on survival and thus DPB1 typing may be considered in several clinical circumstances. 34 The enormous diversity in the MHC, particularly those regions encoding for HLA-A, -B and -DRB1, has ensured sufficient 'herd' resistance to a wide variety of potentially fatal illnesses. 35 To date, 5518 class I alleles (including HLA-A, -B and -C) and 1612 class II alleles (including HLA-DRB1 and -DQB1) have been identified, leading to several million potential HLA combinations within each haplotype. 36 This diversity presents a huge challenge for those hoping to find an UD for HPC transplantation, which necessitates a greater degree of HLA matching than any other human tissue transplant.
There are, however, two key factors that increase the odds of finding a match. First, there is some conservation of HLA haplotypes within ethnic groups, such that certain haplotypes are more common than others. The less ethnically diverse a population is, the more likely it is that two individuals would be matched. This is particularly true of small, isolated populations that exhibit a strong 'founder effect'. 37 (The founder effect refers to the reduction in genetic variation that occurs when a new population is established by a very small number of individuals from a larger population, as may be seen in remote island populations such as Tristan da Cuhna, 38 culturally isolated groups such as the Amish in North America, 39 or certain regions of cities such as Quebec). 40 Second, certain HLA loci (for example, HLA-B and -C) lie closer to each other within the MHC than others, and are less likely to become disassociated from each other by sexual recombination events through the generations. As a result they are found in association more frequently than would be expected from their respective allele frequencies. This phenomenon is known as linkage disequilibrium. 41 Despite this, the chance of two randomly selected Caucasoid individuals being fully matched is estimated to exceed 1 in 20 000.
Inventory size. UD registries must therefore, by necessity, recruit large numbers to create the hugely diverse donor panel required to provide matched UD for the majority of those without an HLAidentical sibling. Anthony Nolan was the first UD registry to be set up precisely for this purpose, 43 and other countries soon followed suit. In 1988, the Immunobiology Working Party of the European Group of Blood and Marrow Transplantation set up Bone Marrow Donors Worldwide (BMDW), a voluntary collaboration of stem cell donor registries and cord blood banks whose goal was to provide centralised information on the HLA phenotypes of stem cell donors. Today, over 18 million UDs and half a million cord blood units are currently searchable via BMDW, provided by 66 registries from 47 countries across the world. 44 In addition, the shift from painstaking paper searches to the provision of an electronic database capable of being searched worldwide via the Internet has dramatically improved search efficiency.
The law of diminishing returns. Although there exist in every population particularly common phenotypes that may be shared by several thousand people, the majority of individuals will possess far less common combinations of the key HLA genes. However, as the size of a registry increases, the chance of identifying a new phenotype falls. Figure 1 . Key factors implicated in delaying UD provision.
Provision of unrelated HPC donors RN Lown and BE Shaw and cord blood units had an HLA-A, -B and -DR split phenotype that was not yet present in the BMDW database. However, by 2010 only 1 in 15 donors and cord blood units added a new HLA-A, -B and -DR split phenotype to the database. 45, 46 The cost to the donor registries of matching scarce phenotypes is becoming increasingly prohibitive.
Ethnic diversity in the donor population. Recruiting ethnic minority groups as HPC donors remains a chronic problem for UD registries. 47 Simply attempting to match the background population proportions is not enough to provide the phenotypic diversity required to give patients from an ethnic minority background the same chance of finding an UD as those of a Caucasian background. 48 For this reason, any single national registry will be intrinsically limited in its ability to provide for its ethnic minority populations: instead there is a necessary reliance on the import of stem cell donations from the international donor community, as well as ensuring that attrition rates of donors from ethnic minority backgrounds are minimised. 45 The foundation of donor registries in countries such as India, China, Taiwan and Thailand will go some way to meeting the needs of their respective é migré s but, other than South Africa, no African or West-Indian registries are currently listed on BMDW.
Resolving resolution. Progress in the field of DNA sequencing has enabled very fine discrimination between HLA alleles. Traditionally, serological (Ab-based) techniques identified 'broad' and 'split' HLA types (antigenic, or low-resolution, typing), but newer DNAbased phenotyping methods have enabled individual alleles to be identified. 49 (Definitions of different levels of typing resolution may be found in Table 1 .) By reducing the incidence of hidden mismatches, transplant outcomes are improved. 9, 50 More established registries might have thousands of donors recruited and typed many years or decades ago, when only serological techniques were available. Out of financial or technological necessity many donor registries perform limited typing of their new donors, either through use of low-resolution typing, through typing at just two HLA loci (for example, HLA-A and -B), or both. 51 Even by 2008, nearly 20% of donors listed in BMDW were typed at low resolution for A and B alone 2 (and thus far less likely to be selected for CT), and 15 registries typed by serological methods only. 52 For the majority of others, intermediate-resolution HLA typing at HLA-A and -B, and highresolution typing at -DRB1 is the norm. Although a number of potential matches may be identified from an initial search request, many of these may subsequently be mismatched when high-resolution CT is performed. It may then be necessary to revisit the initial search and select more donors for CT, further delaying the process.
It has thus become a priority for donor registries to increase the number of new donors typed to high resolution at -A, -B, -C and -DRB1, and many are now implementing this policy at registration. This benefits both the transplant centre and registry: the matching process is expedited, and the registry's donors are more likely to be selected for transplant, with incumbent financial benefits. Such fiscal rewards cannot be overlooked as it costs considerably more to type a donor at high resolution.
Secondary donor selection criteria and HPC source. Many Caucasoid patients will have the luxury of a several potential 10/10 matched donors available to them, so the transplant centre must then use other characteristics to select the best donor. Although practice and opinion vary considerably between centres, the donor characteristics generally perceived to influence transplant outcomes include age, 53 --55 gender, 56 CMV status, 54,57 parity 56 and ABO blood group. 58, 59 Some, and occasionally all, of the secondary donor characteristics may be unavailable at initial search, leading to delays while these details are established. Although the 'ideal' would be to provide all this information up front, in practice this is difficult. For example, many registries are moving away from typing new donors using venous blood samples, preferring saliva or cheek swabs instead for the sake of convenience and improving donor experience. Unfortunately it is not possible to ascertain CMV Ab status from saliva---it must be determined at the CT stage instead. Additionally, although the technology exists to establish the ABO blood group from saliva, it is not routinely employed, and this practice is unlikely to change in the near future. Age and gender are, of course, generally more easily established.
All registries will, however, have a cohort of donors who have previously been requested for CT for other patients, and these make up a (usually limited) bank of donors typed to high resolution with full virology and ABO typing. If one is found to be a match at initial search, access to these donors is usually swift.
Other serological and genetic determinants are occasionally used to discriminate between 10/10 matched donors in transplant practice, such as HLA-DPB1 (refs 31--33,60,61) (as previously discussed) and KIR (killer Ig-like receptor). 62 --71 Further evidence is required, however, before their utility is widely accepted.
The route of HPC donation has changed significantly since the advent G-CSF mobilised PBSC harvest in the late 1990s. In 1997, data collected by the World Marrow Donor Association (WMDA) In contemporary nomenclature, the letter prefix indicates the gene locus (for example, A, B, DRB1); an asterisk then separates this from the first numeric field, which denotes the serological type. The second field denotes the allele (or group of alleles with identical Ag-binding site sequences); the third indicates a synonymous substitution in the coding region; and the last indicates a mutation outside the coding region. A final letter suffix may be added to indicate variations in expression of the molecule showed that over 95% of unrelated adult HPC donations were obtained through BM harvest; by 2006 this figure had dropped to 36%. 2 In 2011, just 13% of donations provided, or imported, by Anthony Nolan were BM. Although not without its own inherent risks, 72 mobilised PBSC harvest is thought to generate greater HPC yields, 73 be more convenient for donors, and have a lower incidence of serious adverse events. 74 There is limited evidence for significant survival differences dependant on the stem cell source (despite obvious differences in certain complications) and thus the product requested varies significantly according to disease, conditioning protocol and physician preference. 75 --83 Additionally, even if a physician requests a particular route of donation, the donor may refuse and, instead, opt for the alternative.
Interpretation of the search report. As can be seen, an in-depth knowledge of HLA haplotype frequencies, linkage disequilibrium, the influence of ethnicity, mistyping errors and the role of other donor discriminators is vital in both the selection of the best UD, and the ability to decide in a timely fashion whether pursuit of an alternative stem cell source is more appropriate. Such expertise exists within donor registries, but often the interpretation of the search report is undertaken by transplant centre staff, who may not have the same depth of knowledge.
Donor availability for CT Once a potentially matched donor has been identified, CT is requested to establish not only a high-resolution phenotype, but to establish donor availability and perform preliminary virology studies (generally CMV, hepatitis B and C, and HIV serology). It is at this stage that considerable delay may be introduced to the search process. Several donor-related issues may arise before CT can take place. The donor may fail to respond to attempts to contact them by letter, telephone or email. The registry may be unable to trace the donor: they have moved house or changed telephone number without informing the registry. The donor may be unwilling to proceed with testing and possible donation (either temporarily or permanently) for personal reasons, may be medically unfit for donation, or may have passed the age limit for donation.
The resultant problem is considerable: in the NMDP in the United States, 46.9% of donors were deferred at 'activation' for domestic requests in the first half of 2011. 84 Of 2002 CT requests in 2011 at Anthony Nolan, 4% of donors were not contactable, had emigrated or were dead, 17% did not proceed for personal reasons, and 6% did not proceed for medical reasons (internal audit), giving an overall 'attrition' rate of 27%.
It is important, then, for donor registries to establish those factors that may predict donor attrition, so they might intervene both at recruitment and during donor latency to be able to create a more readily available donor pool. Switzer et al. 85 published a large prospective cross-sectional study looking at demographic and psycho --social factors influencing donor attrition. Interestingly, donor demographics (for example, gender, age and ethnicity) were not shown to have a significant impact on attrition rates, whereas certain psychosocial factors had a large effect. Through multivariate analysis, blood donors were shown to have the lowest rate of attrition (odds ratio 0.42, Pp0.001), whereas those on the registry 44 years had the highest rate (odds ratio 5.56, Pp0.001). Other factors, such as method of recruitment and concerns about health were important predictors. A follow-on to this study published in 2004 examined psycho --social factors in greater detail: lower rates of attrition were found to be significantly associated with intrinsic commitment to donation, more realistic expectations, fewer medical concerns and greater contact with the donor centre. 24 A further NMDP study examined the effect of donor centre on attrition. The authors showed recruitment in both larger, busier, donor centres, and in those in areas of high population concentration with a higher proportion of minority ethnic groups and less stable populations, were associated with higher rates of attrition. 86 Donor health Strict regulations exist in all developed countries governing the safety of blood and tissue products to be used for allogeneic donation. Such regulations exist to protect the interest of the recipient. In addition, by virtue of the voluntary nature of HPC donation, donor registries and harvest centres are morally obliged not to subject their donors to any risk to their health, whether proven or perceived, which may be avoided. 87 Donors are medically screened at recruitment and again at CT. Considering the time period that may elapse between the two stages (decades in many cases) it is not unusual for health problems that may preclude donation to develop during this time.
Risk to the recipient. As with blood donation, donors with a history of HIV, 88 --92 125 may also be tested for at later stages, and donors with a history of other potentially chronic infections must be considered on a case-by-case basis. The registry also has to consider other potentially transmissible illnesses and, as a rule, a history of malignancy, 126 systemic autoimmune disease 127 --130 and some inherited diseases are not permissible. Donors perceived to be at high risk of contracting HIV and hepatitis are also excluded (although the definition of highrisk behaviour is nebulous and registry policies show marked differences worldwide, particularly with regards to male homosexuality). Some countries exclude donors who have resided in the United Kingdom between 1980 and 1996 from joining, because of concerns about 'variant' Creutzfeldt-Jacob disease, Risk to the donor. As previously mentioned, two routes of HPC donation exist: BM and PBSC harvest. Donors generally undertake a non-binding commitment to be able to donate by both routes at registration. Currently, however, around 70 --80% of donations are PBSC, 137 and under certain circumstances many registries will allow donors to register for PBSC donation only.
Certain donor health conditions preclude donation by either route: moderate-to-severe cardiovascular, respiratory, liver or renal disease, for example. History of uncontrolled hypertension, arrhythmia, diabetes requiring medication, recurrent venous thrombosis, symptomatic haemoglobinopathy, epilepsy and severe latex allergy will also prohibit donation.
Obesity is by far the most common cause of donor deferral at recruitment, and accounted for 19% of deferrals at CT at Anthony Nolan in 2010 (internal audit). Registries may determine the eligibility of donors to donate by body mass index (BMI). A BMI cut-off of 435 kg/m 2 is used in the United Kingdom (which is also the definition of morbid obesity), whereas DKMS (Germany), NMDP (USA) and OneMatch (Canada) employ a cut-off of 40 kg/m 2 . Pulsipher et al. 138 showed a slightly higher risk of adverse events related to donation in donors with a BMI 430 kg/m 2 , and BM biopsy is likely to be a more hazardous procedure in the obese patient. 139 However, there is little evidence linking obesity to adverse events in HPC donation. As a result, the decision to prohibit donations from those with morbid obesity is based on epidemiological studies and anaesthetic risk. 152 --155 are all significantly greater. Anaesthetic complications may arise from difficulty in assessing the airway, 156 restrictive respiratory physiology with reduced lung volumes 157 and suboptimal gas exchange, 158 cardiac decompensation, 159 increased thrombotic risk 160 and altered drug handling. 161 Donors with a wide range of back complaints may be excluded from donating by BM, where the forces exerted by the harvest procedure are deemed to risk exacerbating pre-existing back conditions. However, these donors are often permitted to donate by the PBSC route.
Assessment of borderline cases. The worldwide donor pool has increased considerably over the last decade and, as a consequence, there has been a paradigm shift away from donor quantity to donor quality. In a sense, this makes the task of deciding donor eligibility much more simple at recruitment, particularly in less clear-cut cases. As rejection of a donor is statistically unlikely to have an impact on HLA diversity within the register, the decision of the recruitment officer or medical officer can be made without being influenced by concern for registry numbers, at least in Caucasoid donors. In practical terms, it means that if there is any doubt regarding the donor's fitness, it is feasible to adopt a 'zero-tolerance' policy towards borderline cases, rejecting all donors where it is uncertain whether their health problems subject them to increased risk by donation.
Permissiveness in assessing donor health. This policy may not be so appropriate at CT or workup, where the medical officer may exercise a certain degree of discretion. A key example is where only one potential donor is available for a patient. Any donor with a clear contraindication to donation should, of course, be deferred: however, medical conditions where the risk to the patient or, indeed, the donor are poorly defined or subject to clinical conjecture need to be carefully considered on a caseby-case basis. In cases where there is a potential risk to the patient, such as a history of donor autoimmune disease or highrisk sexual behaviour, this risk must be weighed against the inferior outcomes associated with delays to transplant and pursuit of alternative treatments. In these cases, it is usually appropriate to discuss the risk with the transplant centre, who will make the final decision on whether they wish to accept the donation.
In cases where the potential risk is to the donor, then the route of donation, donor age and general fitness, and any published evidence supporting the case for deferral must be reviewed to inform the decision. Typical scenarios in this category include donors falling slightly above or below weight limits set by the registry, those who pass the age limit for donation during the search and workup process or between first and subsequent donations, and donors who have undergone major surgical procedures recently enough to exclude them from donation under normal circumstances. The responsibility of the registry/ donor centre is always primarily towards the donor, such that if any concern exists the donor must be deferred.
Delays late in the process of donor provision Late donor attrition. Once the donor is identified and their availability established then the time to harvest is usually limited only by logistical factors such as harvest centre availability and donor travel times. However, unexpected and unpredictable events do occur, which may add considerable delay to the process. Life events or injury may cause the donor to become unavailable, or the donor may fail their medical assessment because of an incidental, but prohibiting, finding, such as structural cardiac disease or an abnormal chest X-ray. Rarely, venous access is difficult and a donor may refuse central venous access or BM harvest.
International borders. Finally, there may be problems in exporting HPC when not intended for use in their country of origin. Each country will have specific regulations governing the import and export of human tissue, and HPC are no exception. In addition, regulations regarding the safety of tissues will vary from country to country, especially with regard to infectious diseases. Donor registries must keep up to date with these regulations in their own country, and be familiar with those overseas in order to ensure there are no delays in the provision of HPC donations.
Shipment is particularly vulnerable to events that may cripple international transit networks, particularly air travel. For example, several transplants were delayed during the Icelandic ash cloud in 2010, and 16 patients in the United Kingdom had delays in receiving stem cells after conditioning had commenced. 162 
STRATEGIES TO SPEED DONOR PROVISION
A summary of strategies devised to improve the speed and efficiency of UD provision is shown in Figure 2 .
At recruitment Modern donor recruitment strategies, particularly in larger registries, have moved away from donor quantity, where unselected donor recruitment leads to decreased marginal benefit to the HLA pool, to donor quality. This is reflected in a number of policies.
Focused recruitment in ethnic minority communities. Barriers to recruiting from ethnic minorities include cultural and religious factors, education and awareness, cost and opportunity. 47 Strategies to overcome these barriers include minority drives that may be linked to a patient of a particular ethnic background, employing public figureheads, collaboration with ethno-specific health charities (such as the African --Caribbean Leukaemia Trust in the United Kingdom), cooperation with press read specifically by minority ethnic groups and providing printed information and marketing literature in foreign languages. 163 Although such strategies have met with some success, it remains difficult to recruit in some ethnic groups. 
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Focused recruitment in geographic areas of proven high HLA diversity. Schmidt et al. 164 looked at 320 000 German donors, specifically analysing the variation in HLA Ag and phenotype frequencies across the country. Areas where phenotypic diversity was higher were identified, and provided a rationale for focused recruitment in these areas, with the hope of identifying greater numbers of new or rare phenotypes than might be gained from unselected recruitment. A similar study is underway in the United Kingdom, specifically looking at geographical HLA diversity in donors of North-European origin. 165 Improving typing resolution. In 2011, Anthony Nolan completed the Get10K campaign, which successfully recruited 10 000 healthy male donors under the age of 30, the population most sought by transplant physicians, and typed them to high resolution at HLA-A, -B, -C, -DRB1 and -DQB1.
An alternative approach is to take existing donors typed only at HLA-A and -B, and retype them at additional HLA loci, for example HLA-DRB1. By carrying this out on donors appearing on search requests as potential matches for patients in need of a transplant, DKMS concluded that the chance of patients finding an HLAmatched UD could be improved. 166 Cord blood collection. There are now many well-established cord blood centres across the world, collectively holding over 500 000 cord units. As the standard of HLA matching is considerably more permissive (recommended 5 --6/6, rather than 9 --10/10), cord blood is invaluable in overcoming the difficulties encountered by transplant centres attempting to match patients with rare phenotypes. The use of cord blood units also has the potential to overcome much of the disadvantage borne by ethnic minority patients, and many countries now aggressively recruit expectant mothers from these backgrounds to donate their child's umbilical cord blood, which would otherwise be discarded. 167 The recruitment of cord blood donors in these groups is perceived to be more readily attainable than adult donors. 168 At search Predictive search tools. Experienced search staff in donor registries have a very broad knowledge of national and global HLA haplotype frequencies and linkage disequilibrium that enables them to make a judgement on how likely it is that a given patient will find a matched UD. Such knowledge is invaluable in identifying those patients in whom the chance of finding a matched UD is very low, and who would benefit from early pursuit of alternative transplant strategies, such as a mismatched, cord blood or haplo-identical transplant. 169 Recently, attempts have been made to consolidate this experience into predictive algorithms that categorise patients according to the likelihood of finding a match. In the United States, the Haplogic system used by the NMDP estimates the likelihood of a donor finding an allele level match at HLA-A, -B and -DRB1, based on haplotype frequencies in the four major US ethnic groups. 170 Similarly, in Germany, the OptiMatch system combines intermediate-resolution donor typing from recruitment with high-resolution three-locus-haplotype frequencies in the underlying population in order to calculate the probability of a donor being matched at each of HLA-A, -B and -DRB1, as well as all three loci combined.
Tiercy et al. 171 developed a broad predictive tool in which patients were ranked as low, intermediate and high probability of finding a donor, according to the presence of rare alleles, unusual allele linkage, and number of potential donors identified in a BMDW search. Hirv et al. 172 developed a simpler, yet equally efficacious, tool, ranking patients according to the population frequency of their HLA-DRB1 allele and DRB1-DQB1 haplotype. Both these techniques were validated retrospectively with positive predicative results. Neither tool was compared against the predictive ability of an experienced senior search scientist.
Donor selection algorithms and graft advisory services. The individual or team performing the initial search and selection of donors for CT may differ by country, region or even centre. This may in some cases be centralised, but may also be performed by medical or nursing staff (with or without specific training) in the transplant centre.
In the United Kingdom, a combination of these approaches is found. Anthony Nolan has initiated a system called Graft Identification and Advisory Service (GIAS) to assist those centres where the search was historically predominantly centre based. GIAS is a centralised service that expedites high-quality graft selection. Although the transplant centre specifies the donor selection algorithm for ranking donors according to local practice (for example, including both HLA and secondary donor characteristics), the GIAS team performs the remainder of the search, selection and request functions. By deferring donor selection to the donor registry, the transplant centre benefits from faster search times and fewer donors selected for CT, with additional financial benefits.
At CT
The 'fit panel' of donors. In order to overcome the delays to donor provision presented by donor attrition, the concept of the 'fit panel' of donors has been proposed. These are donors that are 'fit' not just from a health, age and gender perspective, but those whose contact details are contemporary and current health and availability is already known. Such a panel of donors would speed up CT times considerably, eliminating timely processes such as donor tracing. However, considering most registries have several hundreds of thousands (if not millions) of donors, constantly updating records for donor availability could be a huge financial burden.
As part of its 'Phoenix Initiative' in the United States, the NMDP found a novel way of establishing the availability of a core group of donors. During a trial period, they took all those donors identified as potential matches at initial (preliminary) search (sometimes several hundred donors) and contacted them, with the aim of screening and removing donors 'who are deemed unavailable or medically unsuitable before formal activation.' 84 Establishing donor availability and donor selection were thus performed in parallel, so that availability was known when selecting donors for CT, reducing turnover times. In addition, a core group of available donors was established whose availability at future searches and CT was indicated with a 'readiness score', which would expedite future donor provision by indicating to transplants centres those donors most likely to follow through. Compared with a 46.9% background deferral rate, only 11% of pre-screened donors deferred at activation for domestic requests in the first half of 2011. Similarly, as part of the GIAS program, the search team pro-actively contact UK donors who may act as a backup to ascertain their fitness and availability, even if these donors have not been actively selected for CT.
In addition, registries must prospectively engage those donors most likely to be called to donate, in particular younger donors and those who have already been typed to high resolution. Strategies vary between registries, and the details are beyond the scope of this review, but should be influenced by those demographic and psychosocial factors previously identified as contributing towards donor attrition.
At workup
The backup donor. Delays at the workup stage are often very unpredictable and risk delaying the provision of HPC considerably.
One effective strategy in minimising this impact of donor deferral at a late stage is the provision of a 'backup donor'. Not all patients will have this luxury, but they can be kept on standby and rapidly accessed should the initial donor become unavailable. However, there are cost implications and not all transplant centres will be willing to reserve a backup donor.
Global policy
The World Marrow Donor Association was founded in 1994 as an international collaboration aiming to facilitate the exchange of high-quality haematopoietic stem cells for clinical transplantation worldwide and to promote the interests of donors (www.world marrow.org). It monitors trends in the exchange of HPC products and uses this information to recommend benchmarks for standardised global policy and to identify barriers to donor exchange. 173 Published recommendations include: registry organisation; donor recruitment; donor characterisation; search requests; collection, processing and transport; patient and donor follow-up; and financial and legal liabilities. Regular meetings of the WMDA and its working groups ensure contemporary review and opinions of relevant issues affecting global transplantation.
CONCLUSION
Many pitfalls may be encountered during the provision of an unrelated HPC donor, all of which may cause delays, to the detriment of the patient in need of a transplant. Several strategies are being implemented to reduce such delays, and continued perseverance by national registries as well as continued international collaboration are required to ensure that as many patients as possible are given the opportunity of cure through allogeneic transplantation.
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